156 results
Page 3 of 8
8-K
EX-99.1
qsc8nldn3
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
EX-99.1
e0z1etr md
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am
8-K
EX-99.1
20065xr96ectye4ql8
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
EX-99.1
l0mldq3tefw9mk
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
nxh7 r1h2mw
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
wgj1dg23ppn5r8jjzn
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-99.1
42y4h2k1wx2i62y8i
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am
8-K
EX-99.1
fo8rgn1sx lett
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
s33ks 28xdh7p83dj4
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
EX-10.1
02jrka
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.1
bybl6mg9mkdf7z
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
EX-99.1
8hgdc4rw3 h2m
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
wy1a 3mm6shlgg5pue
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
l3kjij6462
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
5lz4x tehdvq7sa8
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
ce0w5xptltjoqc4 dw
16 Mar 21
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
7:15am